These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

171 related articles for article (PubMed ID: 25760636)

  • 1. Sustained CD4 and CD8 lymphopenia after rituximab maintenance therapy following bendamustine and rituximab combination therapy for lymphoma.
    Yutaka T; Ito S; Ohigashi H; Naohiro M; Shimono J; Souichi S; Teshima T
    Leuk Lymphoma; 2015; 56(11):3216-8. PubMed ID: 25760636
    [No Abstract]   [Full Text] [Related]  

  • 2. Influence of rituximab plus bendamustine chemotherapy on the immune system in patients with refractory or relapsed follicular lymphoma and mantle cell lymphoma.
    Ito K; Okamoto M; Ando M; Kakumae Y; Okamoto A; Inaguma Y; Tokuda M; Yanada M; Yamada S; Emi N
    Leuk Lymphoma; 2015 Apr; 56(4):1123-5. PubMed ID: 24828861
    [No Abstract]   [Full Text] [Related]  

  • 3. Progressive multifocal leukoencephalopathy during rituximab maintenance after rituximab and bendamustine treatment for relapsed follicular lymphoma.
    Lucijanic M; Jaksic O
    Ann Hematol; 2020 Sep; 99(9):2191-2192. PubMed ID: 32556456
    [No Abstract]   [Full Text] [Related]  

  • 4. Clinical impact of bendamustine exposure on lymphopenia risk after bendamustine and rituximab combination therapy for follicular lymphoma: a single-institute retrospective study.
    Yamasaki S; Matsushima T; Minami M; Kadowaki M; Takase K; Iwasaki H
    Ann Hematol; 2022 Jan; 101(1):209-211. PubMed ID: 33392703
    [No Abstract]   [Full Text] [Related]  

  • 5. Recurrent and partially reversible cardiomyopathy occurring during treatment with bendamustine and rituximab.
    Mulay S; Boruchov A
    Leuk Lymphoma; 2015 Mar; 56(3):805-7. PubMed ID: 24913498
    [No Abstract]   [Full Text] [Related]  

  • 6. Extended follow-up of CD4
    Gaiolla R; Hartley S; Beech A; Knight H; Smith D; Bishton M; Fox CP; Martinez-Calle N
    Hematol Oncol; 2021 Feb; 39(1):137-140. PubMed ID: 32860715
    [No Abstract]   [Full Text] [Related]  

  • 7. Efficacy of the combination of rituximab-bendamustine as a second-line treatment in patients with follicular lymphoma who progress after immunochemotherapy: a phase II trial of the Spanish Lymphoma Oncology Group.
    Rueda A; Calvo V; Casanova M; Rodriguez-Abreu D; Aguiar D; Llanos M; Alvarez R; Martinez-Banaclocha N; Alfaro J; Quero C; Blasco A; de la Cruz Merino L; Herrero J; García-Arroyo FR; Provencio M
    Leuk Lymphoma; 2019 Jun; 60(6):1576-1579. PubMed ID: 30516082
    [No Abstract]   [Full Text] [Related]  

  • 8. Bendamustine, bortezomib and rituximab produces durable complete remissions in patients with previously untreated, low grade lymphoma.
    Flinn IW; Thompson DS; Boccia RV; Miletello G; Lipman A; Flora D; Cuevas D; Papish SW; Berdeja JG
    Br J Haematol; 2018 Feb; 180(3):365-373. PubMed ID: 29193021
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Rituximab, bendamustine, and low-dose cytarabine as induction therapy in elderly patients with mantle cell lymphoma: a multicentre, phase 2 trial from Fondazione Italiana Linfomi.
    Visco C; Chiappella A; Nassi L; Patti C; Ferrero S; Barbero D; Evangelista A; Spina M; Molinari A; Rigacci L; Tani M; Rocco AD; Pinotti G; Fabbri A; Zambello R; Finotto S; Gotti M; Carella AM; Salvi F; Pileri SA; Ladetto M; Ciccone G; Gaidano G; Ruggeri M; Martelli M; Vitolo U
    Lancet Haematol; 2017 Jan; 4(1):e15-e23. PubMed ID: 27927586
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Bendamustine plus rituximab versus fludarabine plus rituximab for patients with relapsed indolent and mantle-cell lymphomas: a multicentre, randomised, open-label, non-inferiority phase 3 trial.
    Rummel M; Kaiser U; Balser C; Stauch M; Brugger W; Welslau M; Niederle N; Losem C; Boeck HP; Weidmann E; von Gruenhagen U; Mueller L; Sandherr M; Hahn L; Vereshchagina J; Kauff F; Blau W; Hinke A; Barth J;
    Lancet Oncol; 2016 Jan; 17(1):57-66. PubMed ID: 26655425
    [TBL] [Abstract][Full Text] [Related]  

  • 11. The PARP Inhibitor Veliparib Can Be Safely Added to Bendamustine and Rituximab and Has Preliminary Evidence of Activity in B-Cell Lymphoma.
    Soumerai JD; Zelenetz AD; Moskowitz CH; Palomba ML; Hamlin PA; Noy A; Straus DJ; Moskowitz AJ; Younes A; Matasar MJ; Horwitz SM; Portlock CS; Konner JA; Gounder MM; Hyman DM; Voss MH; Fury MG; Gajria D; Carvajal RD; Ho AL; Beumer JH; Kiesel B; Zhang Z; Chen A; Little RF; Jarjies C; Dang TO; France F; Mishra N; Gerecitano JF
    Clin Cancer Res; 2017 Aug; 23(15):4119-4126. PubMed ID: 28314788
    [No Abstract]   [Full Text] [Related]  

  • 12. Fatal Cache Valley virus meningoencephalitis associated with rituximab maintenance therapy.
    Yang Y; Qiu J; Snyder-Keller A; Wu Y; Sun S; Sui H; Dean AB; Kramer L; Hernandez-Ilizaliturri F
    Am J Hematol; 2018 Aug; 93(4):590-594. PubMed ID: 29282755
    [No Abstract]   [Full Text] [Related]  

  • 13. Late occurrence of Epstein-Barr virus-associated lymphoproliferative disorder in a patient with follicular lymphoma treated with bendamustine and rituximab.
    Muroi K; Sakata-Yanagimoto M; Sato T; Yokoyama Y; Maie K; Kurita N; Obara N; Hasegawa Y; Noguchi M; Chiba S
    Ann Hematol; 2015 Dec; 94(12):2061-2. PubMed ID: 26240012
    [No Abstract]   [Full Text] [Related]  

  • 14. Prolonged lymphocytopenia after bendamustine therapy in patients with relapsed or refractory indolent B-cell and mantle cell lymphoma.
    Saito H; Maruyama D; Maeshima AM; Makita S; Kitahara H; Miyamoto K; Fukuhara S; Munakata W; Suzuki T; Kobayashi Y; Taniguchi H; Tobinai K
    Blood Cancer J; 2015 Oct; 5(10):e362. PubMed ID: 26495859
    [No Abstract]   [Full Text] [Related]  

  • 15. Bendamustine and G-CSF support.
    Imataki O; Uchida S; Yokokura S; Uemura M; Kadowaki N
    Support Care Cancer; 2019 May; 27(5):1581-1582. PubMed ID: 29484498
    [No Abstract]   [Full Text] [Related]  

  • 16. Rituximab, bendamustine and lenalidomide in patients with aggressive B-cell lymphoma not eligible for anthracycline-based therapy or intensive salvage chemotherapy - SAKK 38/08.
    Hitz F; Zucca E; Pabst T; Fischer N; Cairoli A; Samaras P; Caspar CB; Mach N; Krasniqi F; Schmidt A; Rothermundt C; Enoiu M; Eckhardt K; Berardi Vilei S; Rondeau S; Mey U
    Br J Haematol; 2016 Jul; 174(2):255-63. PubMed ID: 27018242
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Obinutuzumab plus bendamustine versus bendamustine monotherapy in patients with rituximab-refractory indolent non-Hodgkin lymphoma (GADOLIN): a randomised, controlled, open-label, multicentre, phase 3 trial.
    Sehn LH; Chua N; Mayer J; Dueck G; Trněný M; Bouabdallah K; Fowler N; Delwail V; Press O; Salles G; Gribben J; Lennard A; Lugtenburg PJ; Dimier N; Wassner-Fritsch E; Fingerle-Rowson G; Cheson BD
    Lancet Oncol; 2016 Aug; 17(8):1081-1093. PubMed ID: 27345636
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Anti Myelin-Associated-Glycoprotein Antibody Peripheral Neuropathy Response to Combination Chemoimmunotherapy With Bendamustine/Rituximab in a Patient With Biclonal IgM κ and IgM λ: Case Report and Review of the Literature.
    Gomez A; Hoffman JE
    Clin Lymphoma Myeloma Leuk; 2016 Jul; 16(7):e101-8. PubMed ID: 27245314
    [No Abstract]   [Full Text] [Related]  

  • 19. Phase II study of bendamustine combined with rituximab in relapsed/refractory mantle cell lymphoma: efficacy, tolerability, and safety findings.
    Czuczman MS; Goy A; Lamonica D; Graf DA; Munteanu MC; van der Jagt RH
    Ann Hematol; 2015 Dec; 94(12):2025-32. PubMed ID: 26411584
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Serum IgG and lymphocyte counts are useful for the early detection of infection in patients receiving bendamustine-rituximab therapy.
    Suzuki M; Koyama D; Ikeda S; Sukegawa M; Teshirogi M; Misawa K; Tsunoda S
    J Clin Exp Hematop; 2022 Jun; 62(2):91-98. PubMed ID: 35153257
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.